BTIG raised the firm’s price target on Denali Therapeutics (DNLI) to $39 from $38 and keeps a Buy rating on the shares as the company regains full rights to investigational therapy DNL593 for GRN-related Frontotemporal Dementia. Noting a “promising” program is back, the firm says it is “curious as prior failure very modestly related,” but notes some caution seems appropriate. With that said, BTIG believes the bigger total addressable market supports raising the price target despite the added risk.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics regains full rights to DNL593
- Denali Regains DNL593 Rights After Takeda Collaboration Ends
- Denali Therapeutics Secures $200 Million Royalty Funding
- Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank
- Denali Therapeutics price target raised to $42 from $32 at H.C. Wainwright